Dyne Therapeutics (NASDAQ:DYN) Receives Buy Rating from Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a research note published on Wednesday,Benzinga reports. Chardan Capital currently has a $50.00 price objective on the stock.

A number of other equities analysts have also commented on DYN. Oppenheimer reiterated an “outperform” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. JPMorgan Chase & Co. lowered Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $43.00 to $35.00 in a research note on Thursday, October 24th. HC Wainwright reiterated a “buy” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday. Morgan Stanley lifted their price objective on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Finally, Stifel Nicolaus lifted their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $51.40.

Dyne Therapeutics Price Performance

NASDAQ DYN opened at $28.39 on Wednesday. Dyne Therapeutics has a fifty-two week low of $9.76 and a fifty-two week high of $47.45. The stock’s 50-day moving average is $32.48 and its two-hundred day moving average is $35.17. The firm has a market cap of $2.89 billion, a P/E ratio of -7.97 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, equities analysts expect that Dyne Therapeutics will post -3.02 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, Director Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the sale, the director now directly owns 234,127 shares of the company’s stock, valued at approximately $8,533,929.15. The trade was a 25.33 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Richard William Scalzo sold 1,390 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $48,024.50. Following the sale, the senior vice president now directly owns 98,568 shares in the company, valued at $3,405,524.40. The trade was a 1.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 158,975 shares of company stock valued at $5,693,789. 20.77% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of DYN. Nisa Investment Advisors LLC raised its stake in shares of Dyne Therapeutics by 904.1% in the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after acquiring an additional 669 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Dyne Therapeutics in the third quarter valued at approximately $34,000. Point72 DIFC Ltd bought a new position in shares of Dyne Therapeutics in the third quarter valued at approximately $36,000. US Bancorp DE raised its stake in shares of Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after acquiring an additional 1,212 shares during the last quarter. Finally, Values First Advisors Inc. bought a new position in shares of Dyne Therapeutics in the third quarter valued at approximately $62,000. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.